Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

35 results about "Trandolapril" patented technology

Trandolapril is used to treat high blood pressure.

Stable pharmaceutical compositions containing an ACE inhibitor

A stable pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutical acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the ACE inhibitor is selected from the group consisting of quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazapril, libenzapril, delapril, cilazapril and combinations thereof; wherein the formation of an internal cyclization product, and / or ester hydrolysis product, and / or oxidation product, has been reduced or eliminated, and the weight percents are based on the total weight of the pharmaceutical composition. The stabilized pharmaceutical compositions of the invention exhibit a number of advantages as follows: (i) the ACE inhibitor or a pharmaceutical acceptable salt thereof present in the compositions is preserved from degradation; (ii) the compositions exhibit extended shelf-life under normal storage conditions; (iii) the effect of moisture on the compositions is minimized; (iv) the compositions exhibit minimal, if any, discoloration over a significant period of time; and (v) the compositions exhibit minimal, if any, instability when employed in the presence of colorants.
Owner:SANDOZ AG

Stable pharmaceutical compositions containing an ace inhibitor

A stable pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutical acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the ACE inhibitor is selected from the group consisting of quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazapril, libenzapril, delapril, cilazapril and combinations thereof; wherein the formation of an internal cyclization product, and / or ester hydrolysis product, and / or oxidation product, has been reduced or eliminated, and the weight percents are based on the total weight of the pharmaceutical composition. The stabilized pharmaceutical compositions of the invention exhibit a number of advantages as follows: (i) the ACE inhibitor or a pharmaceutical acceptable salt thereof present in the compositions is preserved from degradation; (ii) the compositions exhibit extended shelf-life under normal storage conditions; (iii) the effect of moisture on the compositions is minimized; (iv) the compositions exhibit minimal, if any, discoloration over a significant period of time; and (v) the compositions exhibit minimal, if any, instability when employed in the presence of colorants.
Owner:SANDOZ AG

Stable Pharmaceutical Composition Comprising an Ace Inhibitor

InactiveUS20080038342A1Minimize degradationStable pharmaceutical compositionBiocidePill deliveryStress inducedCoronary heart disease
The present invention relates to a stable pharmaceutical composition comprising an ACE inhibitor or a pharmaceutically acceptable salt or derivative thereof. In particular, the invention relates to a pharmaceutical composition, which comprises an ACE inhibitor, or a pharmaceutically acceptable salt or a derivative thereof, and a C16-C28 glyceride. ACE inhibitors useful in the present invention are susceptible to heat and/or mechanical stress-induced degradation. Preferred ACE inhibitors are ramipril, trandolapril, quinapril and pharmaceutically acceptable salts and derivatives thereof. The composition of the present invention may be for use as a medicament for the treatment or prevention of a cardiovascular disease, a coronary heart disease, a cerebrovascular disease, a peripheral vascular disease, arrhythmia, hypertension, cardiac failure, cardiovascular death, myocardial infraction, stroke or angina. The present invention further relates to a method of preparing the pharmaceutical composition of the present invention. The present invention also relates to a method of providing a stable pharmaceutical composition comprising an ACE inhibitor, or a pharmaceutically acceptable salt or derivative thereof, by incorporating a C16-C28 glyceride into the composition. The present invention further relates to a use of C16-C28 glyceride to provide a stable pharmaceutical composition comprising an ACE inhibitor or a pharmaceutically acceptable salt or derivative thereof.
Owner:NICHE GENERICS

Synthetic method of trandolapril key intermediate (2S,3aR,7as)-octahydro-1H-indole-2-carboxylic acid

The invention relates to a synthetic method for trandolapril key intermediate (2S, 3aR and 7as)-octahydro-1H-indole-2-carboxylic acid. The method comprises the following steps: obtaining a pair of cis 1, 2-cyclohexane dimethyl acid mono-methyl ester after refluxing hexahydrophthalic anhydride by methanol, splitting the cis 1, 2-cyclohexane dimethyl acid mono-methyl ester by (-) N, N-dimethyl amino diol to obtain 1, 2-cyclohexane dimethyl acid mono-methyl ester of (1R, cis) and (1S, cis) respectively; refluxing (1R, cis)-1, 2-cyclohexane dimethyl acid mono-methyl ester obtained by reclaiming mother liquor in hydrochloric acid to obtain cyclohexane o-dioctyl phthalate, and cyclizing the cyclohexane o-dioctyl phthalate to obtain an initial raw material of the hexahydrophthalic anhydride; and circulating the processes unceasingly to improve the impurity of the (1R, cis)-1, 2-cyclohexane dimethyl acid mono-methyl ester, and then directly entering a follow-up synthesizing process. The process effectively solves the problems of treatment of (1S, cis) 1, 2-cyclohexane dimethyl acid mono-methyl ester after racemization of (d1)1, 2-cyclohexane dimethyl acid mono-methyl ester and yield of (1R, cis)-1, 2-cyclohexane dimethyl acid mono-methyl ester, improves utilization efficiency of raw materials, reduces cost of products, is more suitable for industrialized production, can effectively improve follow-up reaction efficiency, and saves energy of a system.
Owner:CHONGQING NANSONG CHEMI TECH

Preparation method of trandolapril midbody (2S, 3aR, 7aS)-octahydro-1H-indole-2-carboxylic acid

The invention discloses a preparation method of trandolapril midbody (2S, 3aR, 7aS)-octahydro-1H-indole-2-carboxylic acid, and the preparation method comprises the following steps of: preparing 3-chlorine-2-amino-propionic acid methyl ester hydrochloride by using phosphorous pentachloride and dichloromethane; preparing 3-chlorine-2-acetyl amino-propionic acid methyl ester hydrochloride by using the 3-chlorine-2-amino-propionic acid methyl ester hydrochloride, methylbenzene and acetyl chloride; preparing 2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylic acid by using the 3-chlorine-2-acetyl amino-propionic acid methyl ester hydrochloride, DMF (Dimethyl Formamide) and 1-pyrrole cyclohexene; preparing (2S)-octahydro-1H-indole-2-methyl carboxylat by using the 2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylic acid, methanol and palladium on carbon; preparing the (2S, 3aR, 7aS)-octahydro-1H-indole-2-carboxylic acid by using the (2S)-octahydro-1H-indole-2-methyl carboxylat and the methanol. Compared with the prior art, the preparation method of the trandolapril midbody (2S, 3aR, 7aS)-octahydro-1H-indole-2-carboxylic acid, which is disclosed by the invention, has the advantages of easiness and convenience for process, easiness for control, safety, reliability and low cost.
Owner:大连鼎燕医药化工有限公司 +1

Detection product for distinguishing individualized medication types of trandolapril

The invention provides a detection product for distinguishing individualized medication types of trandolapril as an antihypertensive drug. A preparation method of the detection product comprises the following steps: designing multiplex amplification primers and extension primers respectively according to a plurality of to-be-detected target SNP (single nucleotide polymorphism) loci; preparing a multiplex amplification primer reaction system and an extension primer reaction system; in the reaction systems, performing amplification and single base extension reactions on the target SNP loci simultaneously and respectively by multiple sets of primers; performing time-of-flight mass spectrometry on a product obtained after the single base extension reaction, identifying genotypes of SNP relatedto metabolism of different drugs, and guiding individualized medication of the trandolapril as the antihypertensive drug. The detection product can detect five SNP loci related to trandolapril drug metabolism simultaneously, has the advantages of low cost, no need of synthetic probes, short consumed time, simple and convenient result analysis and extremely wide application field, and can be usedfor auxiliary diagnosis and treatment of hypertensive patients requiring to orally take the trandolapril clinically.
Owner:BIOYONG TECH

Mass spectrometry method for identifying personalized medication of trandolapril through product detection

The invention provides a mass spectrometry method for identifying personalized medication of trandolapril through product detection. The method includes the steps: designing multiple-amplification primers and extension primers separately according to multiple to-be-detected target SNP sites, preparing a multiple amplification primer reaction system and an extension primer reaction system, performing amplification and single-base extension reactions at the target SNP sites simultaneously through multiple sets of primers in the reaction systems, performing time-of-flight mass spectrometry analysis of products obtained after the single-base extension reactions so as to identify the genotypes of SNP related to metabolism of different drugs, and guiding personalized medication of the antihypertensive drug trandolapril. Five SNP sites related to metabolism of the trandolapril drugs can be detected simultaneously, and the method has the advantages of low cost, no needs for synthetic probes, short time consumption, simple and convenient result analysis and extremely wide application fields, and can be applied to auxiliary diagnosis and treatment of hypertensive patients who need to take trandolapril clinically.
Owner:BIOYONG TECH

Medication guiding gene detection reagent kit of hypertension reducing medicine namely trandolapril

The invention provides a medication method and reagent kit of a hypertension reducing medicine namely trandolapril. The medication method comprises the steps of according to multiple objective SNP sites to be detected, respectively designing a multiplex amplification primer and an extension primer; compounding a multiplex amplification primer reaction system and an extension primer reaction system; in the reaction systems, performing amplification and a single-base extension reaction on the objective SNP sites at the same time with multiple sets of primers; and performing flight time mass spectrometric analysis on products after being subjected to the single-base extension reaction, identifying the genotypes of different drug metabolism relevant SNPs according to products of different molecular weight extension primers represented by mass spectrum peaks, and guiding the medication of the hypertension reducing medicine namely the trandolapril. Besides, the invention provides a detectionreagent kit using the method. According to the medication method disclosed by the invention, 5 trandolapril drug metabolism pertinent SNP sites can be detected at the same time, and the medication method has the advantages of being low in cost, free from synthetized probes, short in time consumption, simple and convenient in result analysis, and extremely broad in application field.
Owner:BIOYONG TECH

Method for carrying out mass-spectrography distinguishing on trandolapril individualized medicine application through primer composition

The invention provides a method for carrying out mass-spectrography distinguishing on trandolapril individualized medicine application through a primer composition. The method comprises the followingsteps of: according to a plurality of objective SNP sites to be detected, independently designing a multiplex amplification primer and an extension primer; preparing a multiplex amplification primer reaction system and an extension primer reaction system; in the reaction systems, adopting multiple sets of primers to simultaneously independently carry out amplification and single-base extension reaction on the plurality of objective SNP (single nucleotide polymorphism) sites; and carrying out flight time mass spectrometry on a product subjected to the single-base extension reaction, identifyingthe genotypes of different medicine metabolism related SNPs, and guiding the individualized medicine application of a hypertension lowering medicine, i.e., the trandolapril. The method disclosed by the invention can simultaneously detect five trandolapril medicine metabolism related SNP sites, has the advantages of low cost, short time consumption, simple and convenient result analysis and wide application ranges, does not need to carry out probe synthesis, and can be used for the auxiliary diagnosis and treatment of a hypertension patient who clinically needs to take the trandolapril.
Owner:BIOYONG TECH

Primer composition for distinguishing individualized medication type of trandolapril

The invention provides a primer composition for distinguishing an individualized medication type of an antihypertensive drug trandolapril. A preparation method of the primer composition comprises thefollowing steps: multiple amplification primers and extension primers for multiple to-be-detected target SNP loci respectively; a multiple amplification primer reaction system and an extension primerreaction system are prepared; in the reaction systems, amplification and single-base extension reaction is conducted simultaneously and respectively for the multiple target SNP loci by using multipleprimers; and products obtained after the single-base extension reaction are subjected to time-of-flight mass spectrometry (TOF MS) analysis to identify genotypes of different SNPs related to drug metabolism and guide individualized medication of the antihypertensive drug trandolapril. The primer composition can detect five SNP loci related to trandolapril drug metabolism simultaneously, has the advantages of low cost, no synthesis probe, short time, simple and convenient result analysis and very wide application fields, and can be applied to auxiliary diagnosis and therapy of hypertension patients needing to take trandolapril clinically.
Owner:BIOYONG TECH

Synthetic method of trandolapril key intermediate (2S,3aR,7as)-octahydro-1H-indole-2-carboxylic acid

The invention relates to a synthetic method for trandolapril key intermediate (2S, 3aR and 7as)-octahydro-1H-indole-2-carboxylic acid. The method comprises the following steps: obtaining a pair of cis 1, 2-cyclohexane dimethyl acid mono-methyl ester after refluxing hexahydrophthalic anhydride by methanol, splitting the cis 1, 2-cyclohexane dimethyl acid mono-methyl ester by (-) N, N-dimethyl amino diol to obtain 1, 2-cyclohexane dimethyl acid mono-methyl ester of (1R, cis) and (1S, cis) respectively; refluxing (1R, cis)-1, 2-cyclohexane dimethyl acid mono-methyl ester obtained by reclaiming mother liquor in hydrochloric acid to obtain cyclohexane o-dioctyl phthalate, and cyclizing the cyclohexane o-dioctyl phthalate to obtain an initial raw material of the hexahydrophthalic anhydride; and circulating the processes unceasingly to improve the impurity of the (1R, cis)-1, 2-cyclohexane dimethyl acid mono-methyl ester, and then directly entering a follow-up synthesizing process. The process effectively solves the problems of treatment of (1S, cis) 1, 2-cyclohexane dimethyl acid mono-methyl ester after racemization of (d1)1, 2-cyclohexane dimethyl acid mono-methyl ester and yield of (1R, cis)-1, 2-cyclohexane dimethyl acid mono-methyl ester, improves utilization efficiency of raw materials, reduces cost of products, is more suitable for industrialized production, can effectively improve follow-up reaction efficiency, and saves energy of a system.
Owner:CHONGQING NANSONG CHEMI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products